Preparation for endoscopy

Published on 21/04/2015 by admin

Filed under Gastroenterology and Hepatology

Last modified 21/04/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 3760 times

CHAPTER 2 Preparation for endoscopy

2.1 Management of patients on antithrombotic therapy prior to gastrointestinal endoscopy

The editors would like to acknowledge Bernard Boneu, Luc Maillard, Charles-Marc Samama, Jean-François Sched, Gérard Gay, Thierry Ponchon, Denis Sautereau, Jean-Pierre Arpurt, Christian Boustière, Jean Boyer, Jean Cassigneul, Pierre-Adrien Dalbies, Jean Escourrou, René Laugier, Runo Richard-Molard, Gilbert Tucat, Bruno Vedrenne.

Summary

Introduction

The management of patients taking anticoagulant or antiplatelet drugs is an increasingly common problem prior to endoscopic procedures. The risk of bleeding must be given serious consideration, but without underestimating the risk of discontinuing antithrombotic treatment: bleeding is rarely life-threatening, whereas a thromboembolic event associated with interruption of therapy may be permanently disabling or fatal. It is not possible to formulate guidelines that cover all conceivable clinical scenarios and management of a patient’s antithrombotic therapy must be individualized.

Ideally, any necessary therapeutic adjustments should be undertaken in consultation with the doctor who prescribed the treatment in question, and based on a case-by-case evaluation of the risk–benefit ratio of the planned procedure and the envisaged changes in the patient’s antithrombotic therapy. Unfortunately, in most cases, these ideal conditions do not pertain, for a number of reasons: the patient may have forgotten which doctor prescribed the drug or the doctor may be unavailable; or there may be a difference of opinion or lack of knowledge regarding the respective risks entailed by the procedure and discontinuation of the medication. In deciding what to do, the following factors should be taken into account:

In many countries endoscopists, cardiologists, and hematologists have developed consensus recommendations, which of course are only indicative and may evolve over time, as new information emerges. Several of these guidelines are listed at the end of this chapter.

1 Procedure-related bleeding

There is little information available in the literature concerning the hemorrhagic risk associated with antithrombotic agents. It is reasonable to presume that such therapy increases the risk of bleeding above normal levels by rendering bleeding episodes symptomatic that would go unnoticed in the presence of normal coagulation. However, antithrombotics do not themselves cause bleeding.

Hence, antithrombotics have little impact on procedures whose bleeding risk is low. The following factors should be taken into consideration in assessing the risk of a procedure that is performed on a patient who is taking an antithrombotic:

Procedure risk may be classified as below.

1.2 High-risk procedures

1.2.1 High risk of bleeding

Table 1 summarizes the estimated risks of bleeding with various endoscopic procedures (1% or more), in settings where the bleeding can be managed endoscopically.

Table 1 The estimated risks of bleeding with various endoscopic procedures

Procedure Estimated bleeding risk (%)
Colonic polypectomy 1–2.5
Gastric polypectomy or jumbo/snare biopsy 4
Endoscopic mucosal resection ≤22
Ampullectomy 8
Endoscopic sphincterotomy 2.5–5
Photodynamic therapy ≤6
Endoscopic treatment of esophageal or gastric varices ≤6
Endoscopic hemostasis of vascular lesions ≤5

2 Bleeding associated with antithrombotic therapy

2.1 Antiplatelet drugs

These drugs inhibit platelet function, particularly activation and aggregation.

Aspirin and most NSAIDs inhibit platelet aggregation. Aspirin induces irreversible inhibition of cyclooxygenase. Doses usually range from 75 to 325 mg/day (1–2 mg/kg in practice). Disturbance in clotting is not fully corrected until all platelets have been replaced, which takes 7–10 days.

However, a functional platelet level of 50 × 109/L is regarded as adequate for normal hemostatic function. Platelets are renewed at a rate of 10% per day. Thus, depending on the baseline platelet level, discontinuing treatment for 3–5 days is generally sufficient for a patient to recover their normal hemostatic function. NSAIDs also inhibit cyclooxygenase, albeit reversibly. The duration of action is temporary and is determined by the individual drug’s half-life.

The limited data available suggest that standard doses of aspirin and NSAIDs do not significantly increase the risk of bleeding secondary to endoscopic biopsy, colonic snare polypectomy or biliary sphincterotomy. For snare polypectomy, use of a detachable loop is recommended in the presence of a polyp stalk >1 cm. There are no data concerning polyp resection by endoscopic mucosal resection (EMR) or other high-risk procedures in patients on aspirin therapy.

2.3 Heparins

Heparins are the third family of antithrombotics that are widely used. The main indications for heparins are prophylaxis and therapy of venous thromboembolic disease, including deep venous thrombosis (DVT), pulmonary embolism, acute coronary syndromes, and thrombosis prophylaxis in patients with mechanical cardiac valve prostheses before switching to oral anticoagulation. Only low-molecular weight heparins (LMWHs) are used for DVT prophylaxis, in doses ranging from 2000 to 5000 U once daily according to the thrombosis risk level and the product used. The bleeding risk with these doses is low, becoming negligible 12 hour following administration. For other indications, either subcutaneous LMWHs or unfractionated heparin administered intravenously is used.

The LMWH doses in such settings vary considerably depending on the preparation used and body weight. If a LMWH is administered twice daily, it is necessary to wait 12–18 hour for the heparin level to return to a level that allows normal hemostasis. If the drug is administered once daily, 24 hour must be allowed. It should be noted that the activated partial thromboplastin time (APTT) is not useful in such cases as it remains normal, even in the presence of persistent heparinemia. The only way to verify the presence of residual heparinemia is the anti-Xa activity level, which should be <0.20 U/mL. The half-life for unfractionated heparin administered intravenously at a dose of 400–600 U/kg per day is 45–90 minutes and normal hemostasis returns 4–6 hour after the infusion ends. In these cases, the APTT may be useful for verifying that clotting has normalized. If unfractionated heparin is administered via two or three injections using the same dose, because of the longer half-life, it is necessary to wait 8–12 hour for normal coagulation to return. Here too the APTT may allow verification of this.

3 Risks associated with discontinuation of antithrombotic therapy

The risk associated with discontinuation of antithrombotic therapy ranges from minor to major, depending on the specific indications involved. Cases of sudden death or coronary stent occlusion within 7 days of discontinuation have been described.

3.1 Patients receiving oral anticoagulants

3.1.1 Indications associated with acute thromboembolic risk (Table 2)

When taking a patient off warfarin, it is essential to use a specific protocol (Box 2) involving unfractionated heparin. It is also advisable to carefully weigh whether the planned procedure is truly indicated, and if so, undertake procedures associated with a low risk of bleeding (e.g. insertion of a biliary stent without sphincterotomy).

Table 2 Conditions associated with acute thromboembolic risk during interruption of antithrombotic therapy

Condition Target INR
All prosthetic metal valves in a mitral position 3–4.5
All first-generation metal aortic valves 3–4.5
Second-generation aortic valves in patients with an additional embolic risk factor 3–4.5
Atrial fibrillation associated with other thromboembolic risk factors, particularly mitral valve disease 2–3

3.2 Patients receiving antiplatelet drugs

3.2.1 Indications associated with acute thromboembolic risk (Box 4)

Bare (uncoated) metal coronary stents require 1 month for re-endothelialization, while this process may take at least 6 months for drug-eluting stents. Until this occurs, there is a 50% risk of acute myocardial infarction or death. A patient should only be taken off antiplatelet drugs after consulting the cardiologist or other specialist responsible for the patient and where possible, therapy should be restarted within 5 days as the thrombosis risk increases after this time. Unfractionated heparin alone or therapeutic dose LMWH should be used. Again, low-risk procedures should be used where possible if endoscopy cannot be deferred.

4 Switching from warfarin or antiplatelet drugs to alternative therapy

No drug has been approved for switching from warfarin or antiplatelet therapy. The discontinuation/switching procedure takes account of the treatment currently being used and the patient’s thromboembolic risk factors (Boxes 2 and 4).

Calcium heparin may also be effective. The total required dose per 24 hour (in units) is the same as or slightly higher than the dose needed for continuous infusion. The drug can be administered by two or three daily subcutaneous injections. The efficacy of therapy is assessed by the APTT. The target APTT ratio should be 2–3. If heparin levels are measured to guide results, they should be between 0.3 and 0.6 IU/L. If there is a discrepancy between the unfractionated heparin dose injected and the resulting APTT results, measurement of circulating heparin levels is recommended.

The efficacy of switching to LMWH has been validated but guidelines may vary from country to country and local practice needs to be clarified and followed. If LMWHs are used, the dose must be adjusted to the patient’s weight and should be given by one or two subcutaneous daily injections.

A patient can be taken off antiplatelet drugs using preparations with short-term and reversible anti-thrombotic action. However, no treatment of this kind has been validated prospectively.

LMWHs are an alternative and are administered using the same protocol as for switching to warfarin.

6 Recommendations

Further Reading

American Society of Gastrointestinal Endoscopy. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc. 2009;70:1060-1070.

Boustière C, Veitch A, Vanbiervliet, et al. Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2011;43(5):445-461.

Hui AJ, Wong RM, Ching JY, et al. Risk of colonoscopy polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc. 2004;59:44-48.

Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose, effectiveness, and optimal therapeutic range. Chest. 2001;119(1 Suppl):39S-63S.

Samama CM, Djoudi R, Lecompte T, et alAFSSAPS Expert Group. Perioperative platelet transfusion: recommendations of the Agence française de sécurité sanitaire des produits de santé (AFSSAPS)] 2003. and the. Can J Anesth. 2005;52:30-37.

Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001;119(1 Suppl):220S-227S.

Veitch AM, Baglin TP, Gershlick SH, et al. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut. 2008;57:1322-1329.

Yousfi M, Gostout CJ, Baron TH, et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol. 2004;99(9):1785-1789.

Zuckerman MJ, Hirota WK, Adler DG, et al. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. Gastrointest Endosc. 2005;61:189-194.

2.2 Antibiotic prophylaxis

Summary

Introduction

Previously, antibiotics have been prescribed for three indications associated with endoscopic procedures:

European and American Society guidelines (Table 1) have recently changed significantly with respect to antibiotic prophylaxis against infective endocarditis. Antibiotics are no longer recommended for gastrointestinal procedures in the absence of established infection, but are still recommended for patients with evidence of infection prior to endoscopy and in patients undergoing specific procedures, which are discussed below.

Table 1 Specific society recommendations for prophylaxis of infective endocarditis in high risk patients

Society Recommendation Further Reading
AHA 2007 Prophylaxis against infective endocarditis is not recommended for non-dental procedures such as transesophageal echocardiogram, EGD or colonoscopy in the absence of active infection. Wilson et al 2007; Nishimura et al 2008
NICE 2008 Antibiotic prophylaxis for gastrointestinal procedures is not recommended. Richey et al 2008
ESC Antibiotic prophylaxis is not recommended for gastroscopy, colonoscopy, or transesophageal echocardiography. Habib et al 2009
BSG Antibiotics are not indicated as prophylaxis against infective endocarditis. Allison et al 2009
ASGE Antibiotic prophylaxis for infectious endocarditis is not recommended. Banerjee et al 2008

AHA, American Heart Association; NICE, National Institute for Heath and Clinical Excellence; ESC, European Society of Cardiology; BSG, British Society of Gastroenterology; ASGE, American Society of Gastrointestinal Endoscopy.

1 Antibiotics for the prevention of infective endocarditis

European and American societies have recently significantly altered their recommendations for endocarditis prophylaxis in patients undergoing endoscopy (see Further Reading). The rationale for these changes has been summarized by the European Society of Cardiology:

3 Antibiotic prophylaxis for specific endoscopic procedures

See Table 3 for recommended antibiotics based on the British Society of Gastroenterology guidelines.

Table 3 Recommended antibiotics for prophylaxisa

Procedure Antibiotic coverage
ERCP Ciprofloxacin 750 mg PO 90 min pre-procedure
or
Gentamicin 1.5 mg/kg IV
OLT undergoing ERCP Ciprofloxacin 750 mg 90 min pre-procedure
or
Gentamicin 1.5 mg/kg IV
PLUS
Amoxicillin 1 g IV or vancomycin 20 mg/kg IV infused over at least one hour
EUS FNA cystic lesion Co-amoxiclav 1.2 g IV
or
Ciprofloxacin 750 mg PO 90 min pre-procedure
3–5 day course of antibiotics post-procedure is usually given
Antibiotics should be given prior to performing EUS-FNA
PEG Co-amoxiclav 1.2 g IV
or
Second or third generation cephalosporin (i.e. cefuroxime 750 mg IV)
Teicoplanin 400 mg IV can be used in patients who are penicillin allergic
Antibiotics should be given prior to commencing the procedure
Cirrhosis with upper-GI bleed Piperacillin/tazobactam 4.5 g IV three times per day
or
Third generation cephalosporin (i.e. cefotaxime 2 g IV three times per day)

PEG, percutaneous endoscopic gastrostomy; ERCP, endoscopic retrograde cholangiopancreatogram; OLT, orthotopic liver transplant; EUS, endoscopic ultrasound; FNA, fine needle aspiration biopsy.

a Based on British Society of Gastroenterology guidelines. Oral antibiotics should be given 60–90 min pre-procedure to allow absorption of the drug.

Further Reading